Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial
Gerardo Rosati, Sara Lonardi, Fabio Galli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)
Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
Scientific Reports
|
August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports
|
February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
British Journal of Cancer
|
October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
A Ruzzo, F Graziano, Fabio Galli, et al.
Frontiers in Oncology
|
April 24, 2025
Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice
Stefania Gori, Alessandra Fabi, Catia Angiolini, et al.
Scientific Reports
|
November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients
Annamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
Cancers
|
October 14, 2023
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study
Stefania Gori, Alessandra Fabi, Catia Angiolini, et al.
Journal of Gynecologic Oncology
|
July 1, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial
Kenichi Harano, Roldano Fossati, Beatriz Pardo, et al.
Therapeutic Advances in Medical Oncology
|
February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trial
Sandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial
Gerardo Rosati, Sara Lonardi, Fabio Galli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)
Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
Scientific Reports
|
August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports
|
February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
British Journal of Cancer
|
October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
A Ruzzo, F Graziano, Fabio Galli, et al.
Frontiers in Oncology
|
April 24, 2025
Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice
Stefania Gori, Alessandra Fabi, Catia Angiolini, et al.
Scientific Reports
|
November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients
Annamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
Cancers
|
October 14, 2023
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study
Stefania Gori, Alessandra Fabi, Catia Angiolini, et al.
Journal of Gynecologic Oncology
|
July 1, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial
Kenichi Harano, Roldano Fossati, Beatriz Pardo, et al.
Therapeutic Advances in Medical Oncology
|
February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trial
Sandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Page
of 6